Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Lucca (Verona, Italy), S. Volpi (Verona, Italy), L. Tenero (Verona, Italy), M. Piazza (Verona, Italy), M. Sandri (Brescia, Italy), M. Cipolli (Verona, Italy), G. Piacentini (Verona, Italy). Electronic nose (E-nose) analysis of exhaled volatile organic compounds (VOCs) distinguishes pediatric patients (pts) with Cystic fibrosis (CF) from healthy controls (HC) and depicts disease status. 353

Member's Comments

No comment yet.

Related content which might interest you: Detection of differences in volatile organic compounds (VOCs) by ion mobility spectrometry (IMS) of exhaled breath in patients with interstitial lung diseases (ILDs) compared to healthy controls (HC) Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Presence of volatile organic compounds (VOC) in exhaled breath in patients diagnosed with lung cancer (LC) vs healthy patients. Preliminary data Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Lung clearance index (LCI) and trapped gas (TG) may reflect different aspects of Cystic Fibrosis (CF) lung disease in infants Source: Eur Respir J 2003; 22: Suppl. 45, 228s Year: 2003 New contributions in the determination of volatile organic compounds (VOC) in lung cancer (LC) Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Comparison of functional residual capacity (FRC) measured by plethysmography (FRCpleth) and multiple breath washout (FRCmbw) in schoolchildren with cystic fibrosis (CF). Source: International Congress 2018 – Respiratory physiology and measurements Year: 2018 Correlation of induced sputum (IS) particles size distribution (PDS) and pulmonary function test (PFT) in asthmatics patients (A-pts) Source: Eur Respir J 2004; 24: Suppl. 48, 604s Year: 2004 Breath volatile organic compound (VOC) patterns in adult asthma patients of the ALLIANCE cohort Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Relationship between nasal potential difference (NPD) and respiratory function in cystic fibrosis (CF) patients Source: Eur Respir J 2001; 18: Suppl. 33, 125s Year: 2001 Integrating monitoring of volatile organic compounds (VOCs) in asthma and COPD into the routine lung function Source: International Congress 2015 – The next generation of lung function tests Year: 2015 Lung Clearance Index (LCI) derived from N2-Multiple Breath Washout (MBW) depicts worsening in airways colonization in pediatric Cystic Fibrosis (CF) patients (pts) Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Variability of multiple breath washout (MBW) assessment of functional residual capacity (FRC) in cystic fibrosis (CF) patients using an ultrasonic device Source: Eur Respir J 2003; 22: Suppl. 45, 129s Year: 2003 Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Influence of bacterial colonization (BC) on the level of systemic inflammatory markers (SIM) in COPD patients (pts) Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Breath volatile organic compound (VOC) COPD study at two DZL centers - Evaluation of site-specific VOC Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015 Lung mechanic (LM) and gas exchange (GE) in patients with occupational COPD depending on toxic substances Source: Eur Respir J 2001; 18: Suppl. 33, 92s Year: 2001 Identification of exhaled volatile organic compounds (VOCs) associated with loss of asthma control Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Clinical application of the inert gas multiple breath washout technique (MBW) in children with cystic fibrosis (CF) using a prototype ultrasonic sidestream flow sensor (US) Source: Eur Respir J 2006; 28: Suppl. 50, 704s Year: 2006 Monitoring small airways disease (SAD) in cystic fibrosis (CF) Source: Annual Congress 2011 - Monitoring with lung function tests in airway diseases Year: 2011 Volatile organic compounds (VOCs) in COPD patients with exacerbation Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011 Influence of cigarette smoking (CS) on the pulmonary complaints (PC), function of the external breathing (FEB) and quality of life (QL) in the practically healthy persons Source: Eur Respir J 2007; 30: Suppl. 51, 165s Year: 2007